Elite in Gastrointestinal Stromal Tumor

Peter Hohenberger

Mannheim, BW, DE 
Elite in Gastrointestinal Stromal Tumor
Mannheim, BW, DE 
OverviewLocationsClinical Research

Overview

Peter Hohenberger practices in Mannheim, Germany. Mr. Hohenberger is rated as an Elite expert by MediFind in the treatment of Gastrointestinal Stromal Tumor. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Desmoid Tumor, Pancreaticoduodenectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 208 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 63 articles and participated in 2 clinical trials in the study of Gastrointestinal Stromal Tumor.

Gender
Male

Locations

Mannheim, BW, Germany
Other Locations
Heidelberg, BW, Germany
BG Trauma Center Ludwigshafen, Ludwigshafen Am Rhein, RP 67071, Germany
Salem, BW, Germany
Charité Universitaetsmedizin BerlinCampus
Berlin, BE, Germany
Karlsruhe, BW 76021, Germany
Bad Saarow, BB, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)
A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)
Enrollment Status: Completed
Publish Date: April 24, 2023
Intervention Type: Procedure, Radiation
Study Phase: Not Applicable
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: Prospective Multicenter-Multinational Trial in Patients Undergoing Targeted Therapy With a TKI Inhibitor.
Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: Prospective Multicenter-Multinational Trial in Patients Undergoing Targeted Therapy With a TKI Inhibitor.
Enrollment Status: Completed
Publish Date: April 07, 2022
Intervention Type: Diagnostic test
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma
A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

208 Total Publications

Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial).
Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hohenberger's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile